Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anesiva has completed its public offering of 11.1 million shares of its common stock and the exercise by the underwriters of their option to purchase an additional 1.24 million shares.
Subscribe to our email newsletter
The gross proceeds, before deducting underwriting discounts and offering expenses, from the sale of the aggregate 12.34 million shares were approximately $50 million and the net proceeds, after deducting underwriting discounts and offering expenses, were approximately $47.7 million.
Pacific Growth Equities, Broadpoint Capital, and Fortis Securities acted as underwriters for this offering. Anesiva is a biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for pain management.